InMed Pharmaceuticals (INM) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
4 Nov, 2026Executive summary
Q1 FY2027 net loss was $2.331M versus $1.727M a year earlier; cash and cash equivalents were $1.094M at September 30, 2026.
Operations are focused on pharmaceutical R&D after BayMedica Commercial wound down; significant resources are not currently planned for advancing drug candidates.
Proposed Mentari merger and ~US$490M in private-placement financing are central to the outlook; proposed CVRs could provide eligible shareholders with proceeds from future legacy-asset monetization, but none are assured.
Financial highlights
Continuing-operations net loss was $1.995M versus $1.830M; total net loss included a $336K discontinued-operations loss versus $103K income a year earlier.
Continuing-operations operating expenses were $2.009M, up 4% YoY; R&D expense fell 64% to $206K, while G&A rose 46% to $1.803M, primarily on merger costs.
Basic and diluted loss per share was $0.42 versus $0.44 YoY; continuing-operations loss per share was $0.36 versus $0.46.
Cash used in operating activities was $1.142M versus $1.931M a year earlier; quarter-end cash and cash equivalents were $1.094M versus $2.194M at June 30, 2026.
Outlook and guidance
Available cash was expected to fund planned operating and capital needs into mid-November, subject to spending and merger timing; additional capital is required to sustain operations.
Merger closing was expected in Q4 2026, subject to closing conditions and required approvals; Mentari financing is intended to support operations into 2029 and through Phase 2a readouts for two lead PACAP-targeted programs.
If the merger does not close, funding or strategic transactions may be pursued; capital may not be secured on acceptable terms or at all.
If the merger does not proceed and funding is obtained, R&D expense is expected to rise substantially; no material product-candidate revenue is expected for several years, if ever.
Latest events from InMed Pharmaceuticals
- Merger with Mentari, $490M financing, and legacy asset monetization define the fiscal year.INM
Q4 2026 - All-stock merger forms a $421.4M migraine therapy company with funding through 2028.INM
M&A announcement - Q3 2026 net loss rose to $3.0M as R&D costs increased and commercial operations wind-down began.INM
Q3 2026 - Plans to raise up to $50M via flexible securities offerings amid ongoing financial challenges.INM
Registration filing - Lead Alzheimer's candidate shows robust preclinical results; clinical trials targeted for 2027.INM
Sidoti March Small-Cap Virtual Conference - Revenue dropped 26% as INM-901 advanced, with cash reserves and regulatory risks in focus.INM
Q2 2026 - INM-901 shows strong preclinical promise for Alzheimer's, with commercial revenue supporting R&D.INM
H.C. Wainwright 27th Annual Global Investment Conference - INM-901 shows neuroprotection and cognitive improvement in preclinical Alzheimer's models.INM
Status Update - Promising preclinical data in Alzheimer's and dry AMD, with strong financial and commercial support.INM
Emerging Growth Conference 72